Conditions: Hepatocellular Carcinoma (HCC)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 137
Healthy volunteers: no

Brief summary:
The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.

Detailed description:

Arms:
arm 1: no comparator to brivanib

Interventions: intervention 1: brivanib (active)
Intervention descriptions: intervention 1: Tablet, Oral, Brivanib 800 mg, once daily, until progression

Protocol document: